{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:57:27Z","timestamp":1792796247548,"version":"4.5.0"},"reference-count":36,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003837","name":"Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care","doi-asserted-by":"publisher","award":["17KI185"],"award-info":[{"award-number":["17KI185"]}],"id":[{"id":"10.13039\/501100003837","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Program for Dissemination of the Tenure-Track System in Japan by MEXT","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Research Foundation for Pharmaceutical Sciences","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Inohana Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"JSPS","award":["16H06671"],"award-info":[{"award-number":["16H06671"]}]},{"name":"JSPS","award":["21H05506"],"award-info":[{"award-number":["21H05506"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,12,6]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>With the increased use of immune checkpoint inhibitors (ICIs), side effects and toxicity are a great concern. Anaphylaxis has been identified as a potential adverse event induced by ICIs. Anaphylaxis is a life-threatening medical emergency. However, the mechanisms and factors that can potentially influence the incidence and severity of anaphylaxis in patients with cancer remain unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Healthy, murine colon 26, CT26, breast 4T1, EMT6, and renal RENCA tumor-bearing mice were treated with an anti-PD-L1 antibody (clone 10F.9G2). Symptoms of anaphylaxis were evaluated along with body temperature and mortality. The amounts of antidrug antibody and platelet-activating factor (PAF) in the blood were quantified via ELISA and liquid chromatography-mass spectrometry (LC-MS\/MS). Immune cells were analyzed and isolated using a flow cytometer and magnetic-activated cell sorting, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Repeated administration of the anti-PD-L1 antibody 10F.9G2 to tumor-bearing mice caused fatal anaphylaxis, depending on the type of tumor model. After administration, antidrug immunoglobulin G (IgG), but not IgE antibodies, were produced, and PAF was released as a chemical mediator during anaphylaxis, indicating that anaphylaxis was caused by an IgG-dependent pathway. Anaphylaxis induced by 10F.9G2 was treated with a PAF receptor antagonist. We identified that neutrophils and macrophages were PAF-producing effector cells during anaphylaxis, and the tumor-bearing models with increased numbers of neutrophils and macrophages showed lethal anaphylaxis after treatment with 10F.9G2. Depletion of both neutrophils and macrophages using clodronate liposomes prevented anaphylaxis in tumor-bearing mice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Thus, increased numbers of neutrophils and macrophages associated with cancer progression may be risk factors for anaphylaxis. These findings may provide useful insights into the mechanism of anaphylaxis following the administration of immune checkpoint inhibitors in human subjects.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-005657","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T10:48:37Z","timestamp":1671619717000},"page":"e005657","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Tumor-associated neutrophils and macrophages exacerbate antidrug IgG-mediated anaphylactic reaction against an immune checkpoint inhibitor"],"prefix":"10.1136","volume":"10","author":[{"given":"Takahiro","family":"Arai","sequence":"first","affiliation":[{"name":"Lratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kokubo","sequence":"additional","affiliation":[{"name":"Lratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiheng","family":"Tang","sequence":"additional","affiliation":[{"name":"Lratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"},{"name":"Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Abo","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology and Immunology, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayu","family":"Terui","sequence":"additional","affiliation":[{"name":"Lratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jotaro","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology and Immunology, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Akita","sequence":"additional","affiliation":[{"name":"Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology and Immunology, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Hisaka","sequence":"additional","affiliation":[{"name":"Lratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3899-0508","authenticated-orcid":false,"given":"Hiroto","family":"Hatakeyama","sequence":"additional","affiliation":[{"name":"Lratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"},{"name":"Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"2025100302143396000_10.12.e005657.1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.126811"},{"key":"2025100302143396000_10.12.e005657.2","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jaci.2016.02.015","article-title":"Human IgE-independent systemic anaphylaxis","volume":"137","author":"Finkelman","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2025100302143396000_10.12.e005657.3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cellimm.2014.03.018","article-title":"Macrophages are the dominant effector cells responsible for IgG-mediated passive systemic anaphylaxis challenged by natural protein antigen in BALB\/c and C57BL\/6 mice","volume":"289","author":"Jiao","year":"2014","journal-title":"Cell Immunol"},{"key":"2025100302143396000_10.12.e005657.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.02.008"},{"key":"2025100302143396000_10.12.e005657.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-544742"},{"key":"2025100302143396000_10.12.e005657.6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45232"},{"key":"2025100302143396000_10.12.e005657.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.08.001"},{"key":"2025100302143396000_10.12.e005657.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.210"},{"key":"2025100302143396000_10.12.e005657.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2025100302143396000_10.12.e005657.10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.anai.2021.03.008","article-title":"Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor-monoclonal antibodies and desensitization","volume":"126","author":"Labella","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025100302143396000_10.12.e005657.11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2017.06.003","article-title":"The pathophysiology of anaphylaxis","volume":"140","author":"Reber","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2025100302143396000_10.12.e005657.12","doi-asserted-by":"publisher","DOI":"10.1139\/o59-099"},{"key":"2025100302143396000_10.12.e005657.13","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1007\/s00216-014-7736-5","article-title":"Quantitative determination of major platelet activating factors from human plasma","volume":"406","author":"Kim","year":"2014","journal-title":"Anal Bioanal Chem"},{"key":"2025100302143396000_10.12.e005657.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.07.033"},{"key":"2025100302143396000_10.12.e005657.15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jaci.2016.03.028","article-title":"IgG subclasses determine pathways of anaphylaxis in mice","volume":"139","author":"Beutier","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2025100302143396000_10.12.e005657.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100472"},{"key":"2025100302143396000_10.12.e005657.17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0022-3565(25)39063-4","article-title":"CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo","volume":"242","author":"Terashita","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"2025100302143396000_10.12.e005657.18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000400"},{"key":"2025100302143396000_10.12.e005657.19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.18176\/jiaci.0046","article-title":"Mechanisms of anaphylaxis beyond IgE","volume":"26","author":"Mu\u00f1oz-Cano","year":"2016","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2025100302143396000_10.12.e005657.20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-0806"},{"key":"2025100302143396000_10.12.e005657.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.08.169"},{"key":"2025100302143396000_10.12.e005657.22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246342","article-title":"Cancer cell-derived granulocyte-macrophage colony-stimulating factor is dispensable for the progression of 4T1 murine breast cancer","volume":"20","author":"Yoshimura","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025100302143396000_10.12.e005657.23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25575"},{"key":"2025100302143396000_10.12.e005657.24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1105695108"},{"key":"2025100302143396000_10.12.e005657.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47910-1"},{"key":"2025100302143396000_10.12.e005657.26","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncol"},{"key":"2025100302143396000_10.12.e005657.27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20062602"},{"key":"2025100302143396000_10.12.e005657.28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.2.977"},{"key":"2025100302143396000_10.12.e005657.29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900092"},{"key":"2025100302143396000_10.12.e005657.30","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201041069"},{"key":"2025100302143396000_10.12.e005657.31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104453"},{"key":"2025100302143396000_10.12.e005657.32","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1413520","article-title":"A novel MDSC-induced PD-1-PD-L1+ B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties","volume":"7","author":"Shen","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100302143396000_10.12.e005657.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2064"},{"key":"2025100302143396000_10.12.e005657.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.08.004"},{"key":"2025100302143396000_10.12.e005657.35","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1208\/s12248-014-9582-y","article-title":"A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements","volume":"16","author":"Sailstad","year":"2014","journal-title":"Aaps J"},{"key":"2025100302143396000_10.12.e005657.36","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0061"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:14:47Z","timestamp":1759482887000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,21]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/jitc-2022-005657"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005657","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}